MacroGenics was founded in 2000 by Jeffrey Ravetch, Leroy Hood, Alan Aderem and Ruedi Aebersold. The company completed a first round of Series A financing for $13,500,000. The participants in this financing were InterWest Partners, MPM Management and Orbimed Advisors. A first tranche of $4,000,000 was deposited in the Company's account with a second tranche of $9,500,000 completed in August, 2001. MacroGenics acquired Eliance Biotechnology, a private vaccine discovery company located in Dallas, TX, in 2002. MacroGenics is developing immune-based products including monoclonal antibodies to treat patients with cancer, autoimmune disorders, allergy, or infectious diseases and vaccines to prevent infections in healthy individuals. MacroGenics intends to leverage the technologies developed by its founders in the field of antibody therapeutics. MacroGenics expects to advance many of its targets into clinical testing and seek selective partnerships for both product candidates and the technology.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.

To view this information, you must subscribe to Partneringtools.